AMRUTANJAN:NSE-Amrutanjan Health Care Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 685.05

Change

-8.65 (-1.25)%

Market Cap

INR 20.28B

Volume

0.03M

Avg Analyst Target

INR 670.00 (-2.20%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amrutanjan Health Care Limited produces and sells ayurvedic pain balms in India. It operates through OTC products, Beverages, and Others segments. The company offers pain management products, including pain balms and roll-ons; and back pain roll-ons and lotions, body pain gels, and joint muscle sprays, as well as non-steroidal anti-inflammatory drugs. It also provides congestion management products, such as cold rubs, cough syrups, nasal inhalers, and mints. In addition, the company offers sanitary napkins for women. Further, it provides corn caps; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It also exports its products to Gulf, African, South East, and Asian countries. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-9.05 (-1.14%)

INR1,906.99B 31.80 19.84
DIVISLAB:NSE Divi's Laboratories Limited

-42.60 (-0.85%)

INR1,329.16B 66.98 43.83
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+47.10 (+1.00%)

INR783.04B 45.78 20.22
CADILAHC:NSE Cadila Healthcare Limited

-4.20 (-0.71%)

INR606.00B 28.40 20.02
AUROPHARMA:NSE Aurobindo Pharma Limited

-10.35 (-1.13%)

INR537.25B 10.07 6.30
LUPIN:NSE Lupin Limited

+8.00 (+0.70%)

INR519.42B 42.82 18.73
ALKEM:NSE Alkem Laboratories Limited

-108.50 (-3.09%)

INR419.32B 26.46 19.06
LAURUSLABS:NSE Laurus Labs Limited

-0.60 (-0.09%)

INR347.40B 33.13 21.34
IPCALAB:NSE Ipca Laboratories Limited

-7.55 (-0.36%)

INR265.83B 23.26 16.10
AJANTPHARM:NSE Ajanta Pharma Limited

+26.40 (+1.17%)

INR195.77B 28.92 18.69

ETFs Containing AMRUTANJAN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.26% 57% F 46% F
Dividend Return 0.16% 22% F 4% F
Total Return 36.42% 56% F 45% F
Trailing 12 Months  
Capital Gain 61.07% 52% F 35% F
Dividend Return 0.38% 23% F 12% F
Total Return 61.45% 52% F 35% F
Trailing 5 Years  
Capital Gain 208.03% 78% C+ 84% B
Dividend Return 3.68% 76% C 46% F
Total Return 211.70% 78% C+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 21.07% 57% F 72% C-
Dividend Return 0.57% 55% F 43% F
Total Return 21.65% 57% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 32.42% 89% B+ 79% C+
Risk Adjusted Return 66.77% 80% B- 91% A-
Market Capitalization 20.28B 42% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.14 34% F 37% F
Price/Book Ratio 9.26 17% F 10% F
Price / Cash Flow Ratio 22.59 44% F 25% F
EV/EBITDA 21.06 31% F 33% F
Management Effectiveness  
Return on Equity 32.64% 91% A- 95% A
Return on Invested Capital 26.86% 95% A 95% A
Return on Assets 18.53% 97% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.79 50% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.